Primidone BE study for USFDA submission [Regulatives / Guidelines]

posted by bebac_fan – US, 2018-04-10 01:11 (1590 d 16:45 ago) – Posting: # 18659
Views: 3,352

Couldn't find any approval packages on [email protected], so I'm going to have to use science rather than precedent, shucks.

PEMA and PHB are both active metabolites, but based on the FDA general guidance, I am not sure that triggers a requirement to test for them.

However, the guidance specifically recommends PK samples for metabolites when there may be gut/enteric metabolism. Primidone undergoes autoinduction so it is likely metabolized by 3A4, which is in the gut. I suppose this is a trigger for metabolite monitoring?

Another point about autoinduction, is there are persistent effects on metabolism. A long washout period, determined by turnover number of CYPs should be applied. I am not sure what you guys do in practice. PHB can hang with the best of them (like rifampin) in terms of induction.

Complete thread:

UA Flag
Activity
 Admin contact
22,305 posts in 4,668 threads, 1,587 registered users;
online 10 (2 registered, 8 guests [including 2 identified bots]).
Forum time: Wednesday 17:57 CEST (Europe/Vienna)

There is no point in being precise when you don’t know
what you’re talking about.    attributed to John Tukey

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5